- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OPTIMA MEDICAL INNOVATIONS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 3,140 | +4,32 % | Canadian LP Aurora Cannabis is now 'solely' a medical company | ||
| CANOPY GROWTH | 0,940 | +2,51 % | Is Canopy Growth Stock Going to $0? | ||
| TILRAY BRANDS | 6,360 | +0,47 % | MDMA-Herausforderer Bioxyne punktet mit 112% Umsatzplus. Und was macht Tilray? | ||
| ABBOTT LABORATORIES | 97,40 | -0,38 % | Judge tosses class action suit accusing Abbott of sharing CGM data with Meta, Google | ||
| SINOPHARM | 2,235 | -0,89 % | HSI Closes at 26,765, Up 175 pts; HSTI Closes at 5,260, Down 10 pts; HAIDILAO Up over 6%; HSBC HOLDINGS, TINGYI, SINOPHARM, TIME INTERCON, WANGUO GOLD GP Hit New Highs; Market Turnover Rises | ||
| AMARIN | 12,100 | -1,63 % | Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now | ||
| ACADIA PHARMACEUTICALS | 19,110 | -0,39 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 56,76 | +2,20 % | As BridgeBio's Attruby launch accelerates, CEO shrugs off recent EU pricing pressure fears | ||
| CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals Inc. - 10-Q, Quarterly Report | ||
| AURINIA PHARMACEUTICALS | 12,905 | +5,91 % | Aurinia targets $305M-$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development | ||
| ARGENT BIOPHARMA | 0,019 | -13,95 % | ARGENT BIOPHARMA LIMITED: s708A Cleansing Notice | ||
| CENTR BRANDS | 0,001 | 0,00 % | Centr Brands Corp (2): Centr Brands arranges $50,000 debenture financing | ||
| LABORATORIOS FARMACEUTICOS ROVI | 81,75 | +0,18 % | Rovi 2025 slides: margin gains offset revenue dip, Okedi surges | ||
| AVECHO BIOTECHNOLOGY | 0,005 | 0,00 % | AVECHO BIOTECHNOLOGY LIMITED: Avecho completes recruitment for Phase III interim analysis | ||
| HERON THERAPEUTICS | 1,000 | +0,55 % | Heron Therapeutics, Inc.: Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results | - ZYNRELEF- and APONVIE- Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise- Achieved $154.9 Million in 2025 Net Revenue- Issues Full-Year 2026 Net Revenue Guidance of $173 to $183... ► Artikel lesen |
Das Unternehmen OPTIMA MEDICAL INNOVATIONS CORP kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OPTIMA MEDICAL INNOVATIONS CORP finden Sie auf Wallstreet Online.